<?xml version="1.0" encoding="UTF-8"?>
<collection xmlns="http://www.loc.gov/MARC21/slim">
 <record>
  <leader>     caa a22        4500</leader>
  <controlfield tag="001">469078499</controlfield>
  <controlfield tag="003">CHVBK</controlfield>
  <controlfield tag="005">20180323132942.0</controlfield>
  <controlfield tag="007">cr unu---uuuuu</controlfield>
  <controlfield tag="008">170328e19921101xx      s     000 0 eng  </controlfield>
  <datafield tag="024" ind1="7" ind2="0">
   <subfield code="a">10.1007/BF00169013</subfield>
   <subfield code="2">doi</subfield>
  </datafield>
  <datafield tag="035" ind1=" " ind2=" ">
   <subfield code="a">(NATIONALLICENCE)springer-10.1007/BF00169013</subfield>
  </datafield>
  <datafield tag="245" ind1="0" ind2="0">
   <subfield code="a">Electrophysiologic and anticholinergic effects of pirmenol enantiomers in guinea-pig myocardium</subfield>
   <subfield code="h">[Elektronische Daten]</subfield>
   <subfield code="c">[Haruaki Nakaya, Yuiehi Hattori, Masayuki Endou, Satoshi Gandou, Morio Kanno]</subfield>
  </datafield>
  <datafield tag="520" ind1="3" ind2=" ">
   <subfield code="a">Summary: Since it has been reported that several class I drugs stereoselectively block sodium channels, potassium channels and muscarinic receptors in cardiac tissues, electrophysiologic and anticholinergic effects of enantiomers of pirmenol, a class I antiarrhythmic drug, were examined. Both (+) and (−) pirmenol depressed the maximum upstroke velocity (Vmax) of the action potential in a concentration-dependent manner in guinea-pig papillary muscles driven at 1.0 Hz, and there was no significant difference in the potency of the class I effect between the enantiomers. The onset rates of use-dependent block (UDB) of (Vmax) at 2.0 Hz for 10 µmol/l (+) and (−) pirmenol were 0.30±0.03 and 0.29±0.01 per action potential, and the recovery time constants from UDB for (+) and (−) pirmenol were 27.0±2.7 and 27.7±1.9 s, respectively, indicating no difference in the binding and unbinding kinetics to the sodium channel between the enantiomers. Both (+) pirmenol and (−) pirmenol prolonged action potential duration (APD) at low concentrations (1-10 µmol/l) and shortened it at high concentrations (30-100 µmol/l) Again, there was little difference with respect to the effects on APD between the enantiomers. However, in the isolated guinea-pig left atria (−) pirmenol more potently antagonized the negative inotropic effect of carbachol than (+) pirmenol, and the pA2 values for (+) and (−) pirmenol were 6.41 and 6.71, respectively. The functional study was supported by the radioligand binding experiments using [3H]N-methyl scopolamine ([3H]NMS) in guinea-pig left atrial membranes. Specific ([3H]NMS) binding was competitively displaced by the enantiomers, and the apparent dissociation constant for (+) pirmenol (1.95±0.23 µmol/l) was significantly greater than that for (−) pirmenol (0.90±0.18 µmol/l). These results suggest that pirmenol enantiomers stereoselectively interact with cardiac muscarinic receptors but not so with cardiac sodium and potassium channels.</subfield>
  </datafield>
  <datafield tag="540" ind1=" " ind2=" ">
   <subfield code="a">Springer-Verlag, 1992</subfield>
  </datafield>
  <datafield tag="690" ind1=" " ind2="7">
   <subfield code="a">Pirmenol</subfield>
   <subfield code="2">nationallicence</subfield>
  </datafield>
  <datafield tag="690" ind1=" " ind2="7">
   <subfield code="a">Stereoselectivity</subfield>
   <subfield code="2">nationallicence</subfield>
  </datafield>
  <datafield tag="690" ind1=" " ind2="7">
   <subfield code="a">Muscarinic receptors</subfield>
   <subfield code="2">nationallicence</subfield>
  </datafield>
  <datafield tag="690" ind1=" " ind2="7">
   <subfield code="a">Sodium channel</subfield>
   <subfield code="2">nationallicence</subfield>
  </datafield>
  <datafield tag="690" ind1=" " ind2="7">
   <subfield code="a">Potassium channel</subfield>
   <subfield code="2">nationallicence</subfield>
  </datafield>
  <datafield tag="690" ind1=" " ind2="7">
   <subfield code="a">Use-dependent block</subfield>
   <subfield code="2">nationallicence</subfield>
  </datafield>
  <datafield tag="700" ind1="1" ind2=" ">
   <subfield code="a">Nakaya</subfield>
   <subfield code="D">Haruaki</subfield>
   <subfield code="u">Department of Pharmacology, Hokkaido University School of Medicine, 060, Sapporo, Japan</subfield>
   <subfield code="4">aut</subfield>
  </datafield>
  <datafield tag="700" ind1="1" ind2=" ">
   <subfield code="a">Hattori</subfield>
   <subfield code="D">Yuiehi</subfield>
   <subfield code="u">Department of Pharmacology, Hokkaido University School of Medicine, 060, Sapporo, Japan</subfield>
   <subfield code="4">aut</subfield>
  </datafield>
  <datafield tag="700" ind1="1" ind2=" ">
   <subfield code="a">Endou</subfield>
   <subfield code="D">Masayuki</subfield>
   <subfield code="u">Department of Pharmacology, Hokkaido University School of Medicine, 060, Sapporo, Japan</subfield>
   <subfield code="4">aut</subfield>
  </datafield>
  <datafield tag="700" ind1="1" ind2=" ">
   <subfield code="a">Gandou</subfield>
   <subfield code="D">Satoshi</subfield>
   <subfield code="u">Department of Pharmacology, Hokkaido University School of Medicine, 060, Sapporo, Japan</subfield>
   <subfield code="4">aut</subfield>
  </datafield>
  <datafield tag="700" ind1="1" ind2=" ">
   <subfield code="a">Kanno</subfield>
   <subfield code="D">Morio</subfield>
   <subfield code="u">Department of Pharmacology, Hokkaido University School of Medicine, 060, Sapporo, Japan</subfield>
   <subfield code="4">aut</subfield>
  </datafield>
  <datafield tag="773" ind1="0" ind2=" ">
   <subfield code="t">Naunyn-Schmiedeberg's Archives of Pharmacology</subfield>
   <subfield code="d">Springer-Verlag</subfield>
   <subfield code="g">346/5(1992-11-01), 555-562</subfield>
   <subfield code="x">0028-1298</subfield>
   <subfield code="q">346:5&lt;555</subfield>
   <subfield code="1">1992</subfield>
   <subfield code="2">346</subfield>
   <subfield code="o">210</subfield>
  </datafield>
  <datafield tag="856" ind1="4" ind2="0">
   <subfield code="u">https://doi.org/10.1007/BF00169013</subfield>
   <subfield code="q">text/html</subfield>
   <subfield code="z">Onlinezugriff via DOI</subfield>
  </datafield>
  <datafield tag="908" ind1=" " ind2=" ">
   <subfield code="D">1</subfield>
   <subfield code="a">research-article</subfield>
   <subfield code="2">jats</subfield>
  </datafield>
  <datafield tag="950" ind1=" " ind2=" ">
   <subfield code="B">NATIONALLICENCE</subfield>
   <subfield code="P">856</subfield>
   <subfield code="E">40</subfield>
   <subfield code="u">https://doi.org/10.1007/BF00169013</subfield>
   <subfield code="q">text/html</subfield>
   <subfield code="z">Onlinezugriff via DOI</subfield>
  </datafield>
  <datafield tag="950" ind1=" " ind2=" ">
   <subfield code="B">NATIONALLICENCE</subfield>
   <subfield code="P">700</subfield>
   <subfield code="E">1-</subfield>
   <subfield code="a">Nakaya</subfield>
   <subfield code="D">Haruaki</subfield>
   <subfield code="u">Department of Pharmacology, Hokkaido University School of Medicine, 060, Sapporo, Japan</subfield>
   <subfield code="4">aut</subfield>
  </datafield>
  <datafield tag="950" ind1=" " ind2=" ">
   <subfield code="B">NATIONALLICENCE</subfield>
   <subfield code="P">700</subfield>
   <subfield code="E">1-</subfield>
   <subfield code="a">Hattori</subfield>
   <subfield code="D">Yuiehi</subfield>
   <subfield code="u">Department of Pharmacology, Hokkaido University School of Medicine, 060, Sapporo, Japan</subfield>
   <subfield code="4">aut</subfield>
  </datafield>
  <datafield tag="950" ind1=" " ind2=" ">
   <subfield code="B">NATIONALLICENCE</subfield>
   <subfield code="P">700</subfield>
   <subfield code="E">1-</subfield>
   <subfield code="a">Endou</subfield>
   <subfield code="D">Masayuki</subfield>
   <subfield code="u">Department of Pharmacology, Hokkaido University School of Medicine, 060, Sapporo, Japan</subfield>
   <subfield code="4">aut</subfield>
  </datafield>
  <datafield tag="950" ind1=" " ind2=" ">
   <subfield code="B">NATIONALLICENCE</subfield>
   <subfield code="P">700</subfield>
   <subfield code="E">1-</subfield>
   <subfield code="a">Gandou</subfield>
   <subfield code="D">Satoshi</subfield>
   <subfield code="u">Department of Pharmacology, Hokkaido University School of Medicine, 060, Sapporo, Japan</subfield>
   <subfield code="4">aut</subfield>
  </datafield>
  <datafield tag="950" ind1=" " ind2=" ">
   <subfield code="B">NATIONALLICENCE</subfield>
   <subfield code="P">700</subfield>
   <subfield code="E">1-</subfield>
   <subfield code="a">Kanno</subfield>
   <subfield code="D">Morio</subfield>
   <subfield code="u">Department of Pharmacology, Hokkaido University School of Medicine, 060, Sapporo, Japan</subfield>
   <subfield code="4">aut</subfield>
  </datafield>
  <datafield tag="950" ind1=" " ind2=" ">
   <subfield code="B">NATIONALLICENCE</subfield>
   <subfield code="P">773</subfield>
   <subfield code="E">0-</subfield>
   <subfield code="t">Naunyn-Schmiedeberg's Archives of Pharmacology</subfield>
   <subfield code="d">Springer-Verlag</subfield>
   <subfield code="g">346/5(1992-11-01), 555-562</subfield>
   <subfield code="x">0028-1298</subfield>
   <subfield code="q">346:5&lt;555</subfield>
   <subfield code="1">1992</subfield>
   <subfield code="2">346</subfield>
   <subfield code="o">210</subfield>
  </datafield>
  <datafield tag="900" ind1=" " ind2="7">
   <subfield code="a">Metadata rights reserved</subfield>
   <subfield code="b">Springer special CC-BY-NC licence</subfield>
   <subfield code="2">nationallicence</subfield>
  </datafield>
  <datafield tag="898" ind1=" " ind2=" ">
   <subfield code="a">BK010053</subfield>
   <subfield code="b">XK010053</subfield>
   <subfield code="c">XK010000</subfield>
  </datafield>
  <datafield tag="949" ind1=" " ind2=" ">
   <subfield code="B">NATIONALLICENCE</subfield>
   <subfield code="F">NATIONALLICENCE</subfield>
   <subfield code="b">NL-springer</subfield>
  </datafield>
 </record>
</collection>
